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Lysophosphatidic acid enhances 
survival of human CD34+ cells in 
ischemic conditions
Ivana Kostic1,2,*, Isabel Fidalgo-Carvalho1,*, Sezin Aday1,2, Helena Vazão1,2, 
Tiago Carvalheiro3, Mário Grãos1, António Duarte4, Carla Cardoso5, Lino Gonçalves4, 
Lina Carvalho6, Artur Paiva3 & Lino Ferreira1,2
Several clinical trials are exploring therapeutic effect of human CD34+ cells in ischemic diseases, 
including myocardial infarction. Unfortunately, most of the cells die few days after delivery. Herein 
we show that lysophosphatidic acid (LPA)-treated human umbilical cord blood-derived CD34+ cells 
cultured under hypoxic and serum-deprived conditions present 2.2-fold and 1.3-fold higher survival 
relatively to non-treated cells and prostaglandin E2-treated cells, respectively. The pro-survival effect 
of LPA is concentration- and time-dependent and it is mediated by the activation of peroxisome 
proliferator-activator receptor γ (PPARγ) and downstream, by the activation of pro-survival ERK 
and Akt signaling pathways and the inhibition of mitochondrial apoptotic pathway. In hypoxia 
and serum-deprived culture conditions, LPA induces CD34+ cell proliferation without maintaining 
the their undifferentiating state, and enhances IL-8, IL-6 and G-CSF secretion during the first 12 h 
compared to non-treated cells. LPA-treated CD34+ cells delivered in fibrin gels have enhanced 
survival and improved cardiac fractional shortening at 2 weeks on rat infarcted hearts as compared 
to hearts treated with placebo. We have developed a new platform to enhance the survival of CD34+ 
cells using a natural and cost-effective ligand and demonstrated its utility in the preservation of the 
functionality of the heart after infarction.
Cardiovascular diseases are responsible for the deaths of more than 4 million people in Europe every 
year. About 20 percent of these deaths are related to ischemic heart disease. Although endogenous stem 
cells are mobilized from the bone marrow during ischemic episodes, endogenous resources may not 
provide a critical mass capable of rescuing tissue from ischemic injury1. Therefore, the use of exogenous 
stem cells as a potential therapeutic approach to treat ischemic diseases is under evaluation. CD34+ 
cells represent an effective angiogenic stem cell component and early-phase clinical trials have shown 
that intramyocardial administration of autologous CD34+ cells may improve the functional capacity and 
symptoms of angina and chronic myocardial ischemia2,3. In addition, several pre-clinical studies have 
shown that CD34+ cells transplanted into the infarcted myocardium promote angiogenesis and preserve 
its functionality4,5. For therapeutic efficacy, it is imperative that stem cells or their progenies survive and 
engraft into the host tissue. Unfortunately, most of the cells die a few days after delivery and thus com-
promise the final outcome of the procedure6.
One of the first stresses that the cells encounter during the engraftment process is ischemia7. Injected 
cells tend to form clumps that are forced into potential interstitial spaces between tissue elements. Even 
in the context of well-vascularized tissue, these clumps are avascular, so diffusion is the only source 
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of nutrient and oxygen transport until angiogenesis provides a vasculature. Some methodologies have 
been proposed to augment cell survival in ischemic conditions including the exposure of donor cells to 
temperature shock, genetic modification to overexpress growth factors, transduction of anti-apoptotic 
proteins, co-transplant of cells, or preconditioning the cells with pharmacological agents and cytokines 
(reviewed in refs  7,8). Despite these advances, the proposed methodologies have shown limited effec-
tiveness due to the multi-factorial nature of cell death7, some of them are not cost-effective (for example 
the ones involving recombinant proteins) or are difficult to implement from a regulatory stand-point (for 
example genetic manipulation of the cells4, co-transplant of cells that are processed in the laboratory9).
Here we investigated the pro-survival activity of lysophosphatidic acid (LPA) in CD34+ cells. We have 
used umbilical cord blood CD34+ cells because we had easy access to cord blood samples and because 
previous studies have demonstrated the regenerative potential of these cells in the setting of myocardial 
infarction6,10,11. LPA is a natural phospholipid present in blood serum in micromolar ranges12. It increases 
at least two fold in the serum of patients after an acute myocardial infarction13. Studies have shown 
that LPA prevents apoptosis in hypoxic and serum-deprived mesenchymal stem cells14, serum-deprived 
fibroblasts15, Schwann cells16, renal tubular cells17, macrophages18, and hypoxia-challenged neonatal car-
diomyocytes19. So far, little is know about the role of LPA in human hematopoietic stem/progenitor cells. 
Recent studies have examined the role of LPA in the differentiation of CD34+ cells20,21 but not in CD34+ 
survival under ischemic conditions. We hypothesize that LPA enhances the survival of CD34+ cells in 
ischemic conditions. To verify this hypothesis, we have evaluated the survival of human CD34+ cells in 
suspension or encapsulated in fibrin gels under hypoxia and serum-deprivation conditions. We have 
studied the survival mechanism using pharmacological inhibitors, LPA receptor expression and activa-
tion of pro-survival/inhibition of pro-apoptotic signaling pathways. We have further evaluated the pro-
liferation, differentiation and secretome of LPA-treated versus non-treated CD34+ cells. Finally, we have 
evaluated in vivo CD34+ cell survival and its therapeutic effect in the preservation of cardiac function.
Results
LPA induces CD34+ cell survival in hypoxia and serum-deprivation conditions. Human umbil-
ical cord blood-derived CD34+ cells (2 × 105 cells per well of a 96-well plate) were incubated in X-Vivo 
medium (previously used in clinical trials22) under hypoxic conditions (0.5% O2) at 37 °C, for 24 h. The 
pro-survival effect of LPA as well as drugs approved by FDA for the treatment of cardiovascular diseases 
(e.g. Nebivolol23, Irbesartan24) and drugs being evaluated in pre-clinical/clinical assays to improve heart 
function in patients/models with heart failure (e.g. INO100125, erythropoietin (EPO)26, VX-70227) was 
evaluated (Fig. 1A,B). For comparison purposes, we have tested the drugs at a concentration of 10 μ M. 
This concentration has no cytotoxic effect (results now shown) and is slightly higher than the screenings 
performed before for CD34+ cell expansion28. Drug treatment was maintained during the duration of 
the assay. ABT-263, a pro-apoptotic molecule, was used as positive control for apoptosis. According to 
flow cytometry results, non-treated CD34+ cells show a very poor survival, with only ~31% viable cells 
after 24 h (Fig. 1A). Among seven drugs tested, LPA (P < 0.0001) and prostaglandin E2 (PGE2; P < 0.05) 
improved significantly cell survival (Fig.  1A). LPA was the drug with the highest pro-survival effect 
(~69% viable cells) and therefore further studied. LPA improved cell survival by reverting necrosis and 
apoptosis of CD34+ cells under hypoxic and serum-deprivation conditions (Fig. 1B).
The pro-survival effect of LPA is concentration dependent (between 1 and 100 μ M) being the survival 
of CD34+ cells already statistically significant (P < 0.001) as compared to the control (non-treated cells) 
at 1 μ M LPA (Fig. 1C). Importantly, the percentage of viable cells in CD34+ cells treated with 1 μ M LPA 
and cultured under hypoxia conditions is similar to non-treated cells cultured under normoxia condi-
tions. For subsequent tests a concentration of 100 μ M has been used since the survival effect was max-
imal. The pro-survival effect of LPA decreases as a function of hypoxia time (Supplementary Figure 1). 
The percentage of viable cells in LPA-treated CD34+ cells decreased from 78% at day 1 to 40% at day 3. 
All together, the results obtained indicate that LPA is a pro-survival molecule for CD34+ cells and its 
effect is time and concentration-dependent.
The pro-survival effect of LPA is observed in CD34+ cells encapsulated in fibrin gels. Injectable scaf-
folds are very promising vehicles to deliver stem cells for regenerative medicine since they provide a 
favorable structural support for cell survival and proliferation9,29,30. Several studies have shown that cells 
transplanted with scaffolds in the cardiac setting improved cell survival, induced angiogenesis and pre-
served cardiac function after infarction30–33. Therefore we examined whether LPA could have a similar 
pro-survival effect in cells encapsulated in fibrin gels and cultured under hypoxic conditions. Non-treated 
CD34+ cells had poor survival in fibrin gels (23.2 ± 2.8% viable cells, n = 3, at day 1; 12.6 ± 1.2% viable 
cells, n = 5, at day 3) showing that the matrix alone did not have any pro-survival effect (Fig. 1D). In con-
trast, LPA-treated CD34+ cells encapsulated in fibrin gels presented high survival at later times (day 3) 
relatively to LPA-treated cells not encapsulated in fibrin gels (day 1: 69.0 ± 0.7% vs 76.7 ± 1.5% for 
encapsulated and non-encapsulated, respectively; day 3: 51.1 ± 0.8% vs 37.2 ± 6.6% for encapsulated and 
non-encapsulated, respectively). Overall, the results indicate that the pro-survival effect of LPA is also 
observed in cells encapsulated in fibrin gels.
LPA induces CD34+ cell survival mainly through peroxisome proliferator-activated receptor γ 
(PPAR-γ). To date, up to six LPA receptors (LPARs) have been identified: LPA1-LPA634. Studies also 
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indicate that LPA has a high affinity for peroxisome proliferator-activator receptor γ (PPAR-γ )35,36. To 
identify the expression of all known LPA receptors, we performed real time polymerase chain reaction 
(qRT-PCR). CD34+ cells expressed LPARs 1–6 and PPAR-γ receptors (Fig. 2A). When CD34+ cells were 
cultured in hypoxia conditions for 24 h in the absence of LPA, the expression of the receptors was upreg-
ulated relatively to original CD34+ cells collected from cord blood. This upregulation was likely due to 
the differentiation of the cells (see below) as been noted for mesenchymal stem cells37. When CD34+ cells 
were cultured in hypoxia conditions in the presence of LPA, in general the expression of the receptors 
was lower than in non-treated cells.
To identify the receptor that is mediating the pro-survival effect of LPA (100 μ M), we used Ki16425, 
a LPA1- and LPA3-specific antagonist, 1-bromo-3(S)-hydroxy-4-(palmitoyloxy)butyl]phosphonate (BrP), 
a pan-G protein inhibitor, and GW9662, an antagonist of peroxisome proliferator-activator receptor γ 
(PPAR-γ ). We complemented this approach by inhibiting downstream targets of the receptors including 
Rho kinase by Y-2762/ROCK and the upstream kinases and activators of MAPK/Erk, i.e. MEK1/2 by 
PD98059. It is known that all LPARs couple with and activate G proteins, which in turn activate MAPK 
(LPA1, LPA2, LPA3 and LPA4) and Rho kinase (LPA1, LPA2, LPA4 and LPA5)38. Cells were treated 
for 1 h in X-Vivo medium containing a specific antagonist followed by culture under hypoxia condi-
tions for 24 h in the presence of LPA. Cell survival was assessed by FACS using Annexin V/PI staining. 
Inhibitor concentrations used in this experiment (without LPA treatment) did not affect cell viability 
(data not shown). Our results indicated that PPAR-γ was the main mediator of the pro-survival effect of 
Figure 1. Assessment of CD34+ cell survival under hypoxia and serum-deprivation culture conditions: 
effect of LPA treatment and cell encapsulation. In all studies, CD34+ cells were isolated immediately 
from cord blood, without cryopreservation. (A) Survival, apoptosis and necrosis of CD34+ cells cultured 
in hypoxia for 24 h in serum-free medium with or without drugs. Studies were performed in CD34+ cells 
from 3–6 different donors (with the exception of ABT-263, where 2 donors have been used); 1–8 technical 
replicates per donor. (B) Survival, apoptosis and necrosis of CD34+ cells cultured in serum-free medium 
for 24 h in normoxia, hypoxia and hypoxia with LPA treatment. Studies performed in CD34+ cells from 
4 different donors; 1–8 technical replicates per donor. (C) Effect of LPA concentration on the survival of 
CD34+ cells cultured in serum-free medium for 24 h in hypoxia (black and white columns) or normoxia 
(grey column). Studies performed in CD34+ cells from 3–12 different donors; 1–6 technical replicates 
per donor. (D) Non-treated or LPA-treated cells (1 × 106 cells) encapsulated in fibrin gels (200 μ L) were 
cultured in serum free medium with or without LPA (100 μ M) under hypoxia conditions for 1 or 3 days. 
Studies performed in CD34+ cells from 3-different donors; 1 technical replicate per donor. *Denotes 
statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. In (A,C–E) results are presented as 
mean ± SEM.
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Figure 2. Survival mechanism in LPA-treated CD34+ cells. (A) Expression of LPA receptors. Cells were 
cultured in the different experimental conditions for 24 h. Gene expression was normalized by the expression 
of GAPDH. Studies were performed in CD34+ cells isolated from 3 different donors; 4 technical replicates. 
(B) Involvement of LPA receptors in cell survival. Cells were pre-treated with Rho kinase inhibitor  
(Y-2762), MEK1/2 inhibitor (PD98059), LPA1- and LPA3-specific inhibitor (Ki16425), a pan-G protein 
inhibitor (1-bromo-3(S)-hydroxy-4-(palmitoyloxy)butyl]phosphonate (BrP)), or peroxisome proliferator-
activator receptor γ (PPAR-γ ) inhibitor (GW9662) for 1 h before hypoxia and cell medium containing LPA 
(100 μ M) for 24 h. Cells without any pre-treatment and cultured in serum-free medium with or without 
LPA, in hypoxia for 24 h, were used as positive and negative controls, respectively. Studies were performed 
in CD34+ cells isolated from at least 3 different donors; 1–8 technical replicates. # and * means statistical 
difference relatively to cells without any pre-treatment and cultured in serum free medium without LPA, 
and with LPA, respectively. (C) Percentage of viable cells was measured by FACS. CD34+ cells in hypoxia 
and serum deprived conditions were treated with LPA, LPA with MEK1/2 inhibitor (PD98059; an upstream 
activator of MAPK/Erk), or LPA with Akt inhibitor (MK2206). Studies were performed in CD34+ cells 
isolated from 3 different donors. (D) Gene expression of VEGFA, BAX and CASP9. NT and LPA mean 
non-treated and LPA-treated CD34+ cells in suspension. Gene expression was normalized by the expression 
of GAPDH. (E) Caspase 9 activity in LPA-treated or non-treated CD34+ cells either in suspension (Cells) 
or encapsulated in a fibrin gel (Gels) at 24 h. Activity was assessed by Caspase Glo® 9 Assay kit. (F) 
Gene expression of BAX and CASP9 in fibrin gel encapsulated cells. Gene expression was normalized 
by the expression of GAPDH. In (D–F) studies were performed in CD34+ cells isolated from 3 different 
donors; 4 technical replicates. *,#Denotes statistical significance: *,#P < 0.05, **,##P < 0.01, ***,###P < 0.001, 
****,####P < 0.0001. In all graphs, results are presented as mean ± SEM.
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LPA under the conditions tested (Fig. 2B). The antagonist of PPAR-γ significantly decreased (P < 0.001) 
the number of viable cells induced by LPA from ~77% to ~53%; however, it did not block totally the 
pro-survival effect of LPA, since cells without LPA had a survival of 39% (P < 0.01). The inhibition of 
LPA1 and LPA3 by Ki16425, or the inhibition of G protein signaling by BrP, had a relatively small effect 
in the survival of CD34+ cells (Fig. 2B). The number of viable cells decreased from 77% (+ LPA) to 67% 
(in case of Ki16425, P < 0.01). Importantly, the inhibition of MAPK signaling pathway suppressed the 
pro-survival effect of LPA at higher levels than the inhibition of Rho kinase signaling pathway. Because 
the two signaling pathways are downstream targets of different LPARs (see above), this might indicate 
different contributions of each LPAR in the survival of CD34+ cells.
Since ERK1/2 and PI3K/Akt signaling pathways are very important for cell survival14,15, we evaluated 
whether these pathways were activated in CD34+ cells exposed to LPA. Cells were treated for 1 h in 
X-Vivo medium containing Akt antagonist MK2206 or the upstream kinases and activators of MAPK/
Erk antagonist PD98059 followed by the addition of LPA and culture of the cells under hypoxia condi-
tions for 24 h. Both antagonists significantly decreased the number of viable cells induced by LPA from 
~60% to ~39% (Akt; P = 0.07) and from ~80% up to ~57% (Erk; P < 0.05), respectively (Fig.  2C). We 
complemented these results by analyzing the expression of VEGFA, a pro-survival factor. Indeed, pre-
vious studies have shown that LPA increased VEGF secretion in mesenchymal stem cells39,40. Our gene 
expression results showed that LPA-treated CD34+ cells expressed significantly higher levels of VEGFA 
than non-treated cells for the first 8 h of cell culture (Fig.  2D.1); however, the levels of VEGF protein, 
measured by an ELISA kit at time 24 h, were very low (below the sensitivity limit of the kit, i.e., 16 pg/mL).
Taken together, our data confirmed the expression of receptors LPA1-LPA6 and PPAR-γ receptors 
in CD34+ cells and showed that LPA pro-survival effect in CD34+ cells cultured under hypoxic and 
serum-deprivation conditions is mainly mediated by the activation of PPAR-γ receptor. Although fur-
ther studies need to be performed to show that the inhibition of PPARγ reduces ERK1/2 and PI3K/Akt 
signaling pathways, our current results with Akt and MAPK/Erk antagonists in LPA-activated CD34+ 
cells indicate that both pathways are involved as downstream signaling events of the PPAR-γ receptor 
activation.
LPA inhibits apoptosis by inhibiting the expression of BAX and caspase 9. The pro-survival 
mechanism of LPA was further studied at gene and protein levels. We asked whether the anti-apoptotic 
role of LPA was mediated by the inhibition of mitochondrial-dependent apoptotic pathway. It is known 
that the translocation of BAX from the cytoplasm to the mitochondrial membrane plays an important 
role in the release of cytochome c to the cytoplasm, which leads to the activation of caspase 9 and the ini-
tiation of cell apoptosis41–43. Our results showed that LPA down-regulated significantly BAX and CASP9 
(caspase 9 gene) expression in CD34+ cells after 4 h (BAX) and 12 h (BAX and CASP9) as compared to 
non-treated cells (Fig. 2D.2,D.3). Similarly, LPA down-regulated BAX (8–24 h) and CASP9 (8–24 h) gene 
expression in CD34+ cells encapsulated in fibrin gels (Fig.  2F.1,F.2). These analyses were extended to 
the activity of caspase 9. LPA significantly inhibited the activity of caspase 9 in CD34+ cells cultured in 
ischemic conditions and the inhibition was reversed by PPAR-γ inhibitor (GW9662) but not LPA 1/3 
inhibitor (Ki16425) (Fig.  2E). Therefore our results are in line with previous results showing that LPA 
protects T cells and mesenchymal stem cells from apoptosis by suppression of BAX, i.e., by the inhibition 
of mitochondrial-dependent apoptotic pathway14,42. However, the anti-apoptotic role of LPA in CD34+ 
cells is essentially mediated by PPARγ while in mesenchymal stem cells is mediated by LPA receptors.
LPA induces cell proliferation but it is unable to maintain the undifferentiated state of CD34+ 
cells. LPA is highly mitogenic in quiescent cells44. To determine whether LPA could induce the pro-
liferation of CD34+ cells in hypoxia and serum-deprivation conditions, a suspension of non-treated or 
LPA-treated cells (2 × 105 cells in 200 μ L of X-vivo medium) was exposed to hypoxia for 24 h and then 
cultured under normoxia conditions for 6 additional days. LPA-treated cells increased their number 
approximately 3-fold over the 7 days period while non-treated cells decreased to half their initial number 
(Fig. 3A). Our results show that CD34+ cell proliferation is correlated with an up-regulation of cyclin G 
(CCNG2) at 8 h (Fig.  3B). We complemented these results by monitoring cell cycle by flow cytometry 
in cells cultured in the presence and absence of LPA for 24 h under hypoxic conditions. LPA-treated 
cells cycled more actively than the non-treated cells since more CD34+ cells were found in G2M phase 
(Fig. 3C). Because LPA-treated cells are in lower percentage in S-phase than non-treated cells it is likely 
that they are proliferating faster.
To examine the effect of LPA on CD34+ cell self-renewal/differentiation, CD34+ cells were cultured 
in X-vivo medium supplemented or not with LPA for 1 day under hypoxic conditions or cultured for 1 
day in hypoxia followed by 6 days in normoxia. At the end, cells were characterized by flow cytometry 
for differentiation markers (Supplementary Tables 1 and 2, Supplementary Figures 2 and 3). After 1 day 
of hypoxia, both non-treated and LPA-treated CD34+ cells started to differentiate into mast cells (NT: 
21.7 ± 9.8%, n = 4; LPA: 25.0 ± 13.0%, n = 4) and neutrophils (NT: 7.9 ± 2.0%, n = 4; LPA: 8.7 ± 4.4%, 
n = 4) (Fig.  3D). Only 64.3 ± 4.8% and 58.8 ± 8.7% of the non-treated or LPA-treated CD34+ cells, 
respectively, expressed CD34 marker. Cells cultured for 1 day in hypoxia and then 6 days in normoxia 
further differentiated into several cell lineages including dendritic cells (DCs), basophils, monocytes, 
among others. Similar differentiation profiles were observed for non-treated and LPA-treated cells, 
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without statistical difference (P > 0.05). All together, our results show that LPA induces CD34+ cell pro-
liferation but is unable to maintain their undifferentiated state.
LPA modulates differently cytokine release in CD34+ cells and CD34+ cells encapsulated 
in fibrin gels. The regenerative potential of CD34+ cells in ischemic diseases such as myocardial 
infarction is mainly mediated by the release of paracrine factors45. To determine the effect of LPA in 
the release of signaling cytokines by CD34+ cells and CD34+ cells entrapped in fibrin gels we used 
a cytokine bead array for the following cytokines: interleukin-1β (IL-1β ), IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-8; IL-10, IL-12(p70), IL-13, IL-17, granulocyte colony-stimulating factor (G-CSF), granulocyte/
macrophage colony-stimulating factor (GM-CSF), interferon-γ (IFN-γ ), monocyte chemotactic pro-
tein (monocyte chemotactic activating factor [MCP-1 (MCAF)], macrophage inflammatory protein-β 
(MIP-1β ) and tumor necrosis factor-α (TNF-α ). The cells were incubated in serum-free medium X-Vivo 
under hypoxia conditions and the samples were taken at different time points (4, 8, 12 and 24 h), either 
in the presence or absence of LPA (100 μ M) and PPAR-γ -receptor antagonist GW9662. CD34+ cells in 
suspension (Fig. 4A,B) secreted much higher concentrations of cytokines than cells encapsulated in fibrin 
gels (Fig. 4C). The most secreted cytokine was IL-8 (cells only: 2704.4 ± 234.4 pg/mL; encapsulated cells: 
126.4 ± 21.6 pg/mL, both at 24 h). During the first 12 h, cells in suspension secreted higher levels of IL-8, 
IL-6, and G-CSF than non-treated cells. During the same period of time, cells expressed lower levels of 
MIP-1β (times: 4, 8 and 12 h) and TNF-α (time: 4 h) than non-treated cells. At time 24 h, LPA-treated 
CD34+ cells secreted lower levels of all the measurable cytokines such as G-CSF, IFN-γ , IL-6, IL-8, IL-17, 
Figure 3. Proliferation and differentiation of LPA-treated CD34+ cells. (A) Number of non-treated and 
LPA-treated cells after 1 day in hypoxia and additional 3 (4th day) or 6 days (7th day) in normoxia. Cells were 
treated with 100 μ M of LPA. (B) Gene expression of cyclin G (CCNG2) as assessed by qRT-PCR analyses. 
Gene expression was normalized by the expression of GAPDH. (C) CD34+ cell cycle, as evaluated by flow 
cytometry and PI staining, was performed in LPA- or non-treated cells. (C.1,C.2) show representative FACS 
results for each experimental group. (D) Cell differentiation as measured by flow cytometry using a cocktail 
of antibodies (please see Supplementary Table 2) to identify hematopoietic cell types. Cells were cultured in 
hypoxia for 1 day followed or not by 6 days in normoxia. In all graphs, cells were cultured with or without 
LPA (100 μ M). In all studies were performed in CD34+ cells isolated from at least 3 different donors; 1–5 
technical replicates. *Denotes statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001. In all graphs, results 
are presented as mean ± SEM. In graphs (A–C) NT and LPA mean non-treated and LPA-treated CD34+ cells 
in suspension.
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MCP-1, MIP-1β , and TNF-α than non-treated cells. Therefore, LPA decreased significantly the secretion 
of pro-inflammatory cytokines at 24 h. Importantly, the secretion of most cytokines (with the exception 
of IL-6 and IL-8) at 24 h was restored in cells inhibited with PPAR-γ -receptor antagonist GW9662, indi-
cating that most of cytokine secretion was controlled by PPAR-γ receptor (Fig. 4B).
CD34+ cells encapsulated in fibrin gels (Fig.  4C) showed a different cytokine secretion profile than 
suspended CD34+ cells (Fig.  4A,B). For example, the secretion of IL-17, G-CSF and IFN-γ was not 
observed, while IL-13 cytokine was only observed in CD34+ cells encapsulated in fibrin gels. In fibrin 
gels, LPA-treated cells secreted higher levels of IL-6, IL-8 and MIP-1β than non-treated cells during 
the first 8 h. During the same time, cells expressed lower levels of IL-13 and TNF-α than non-treated 
cells. From 8 to 24 h, LPA-treated cells expressed lower levels of TNF-α but higher levels of IL-8 than 
non-treated cells.
Overall, after 24 h of treatment, LPA decreased the secretion of most of the anti-inflammatory 
cytokines in suspended CD34+ cells relatively to non-treated cells. With the exception of IL-6 and IL-8, 
the differences in cytokine secretion between non-treated and LPA-treated cells were abolished when 
the PPAR-γ inhibitor was used. Our results further show that the encapsulation of the cells in fibrin gels 
changed the magnitude and profile of cytokines secreted by non-treated and LPA-treated CD34+ cells.
Figure 4. Secretome of LPA-treated CD34+ cells. (A) Cytokine secretion as assessed by Bio-Plex analyses 
for non-treated (NT) and LPA-treated (LPA) CD34+ cells (cells in suspension). (B) Cytokine secretion for 
non-treated (NT), LPA-treated (LPA) and LPA + PPAR-γ inhibitor (GW9662)-treated (GW + LPA) CD34+ 
cells at time point 24 h. Cells were in suspension. (C) Cytokine secretion for non-treated (NT) and LPA-
treated (LPA) CD34+ cells encapsulated in fibrin gels. In (A–C) studies were performed in CD34+ cells 
isolated from 3 different donors; 4 technical replicates. *Denotes statistical significance: *P < 0.05, **P < 0.01, 
***P < 0.001. In all graphs, results are presented as mean ± SEM.
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LPA-treated CD34+ cells entrapped in fibrin gels have higher survival in vivo after myocardial 
infarction. To evaluate the survival and therapeutic potential of LPA-treated CD34+ cells (1 × 106 cells), 
cells were suspended in a fibrin gel precursor solution (200 μ L) and injected in the infarcted heart of 
nude rats. Myocardial infarctions were induced by permanent ligation of the left anterior descending 
coronary artery (LAD). Infarcted hearts without any treatment (PBS) or treated with CD34+ cells sus-
pended in a fibrin gel precursor solution were used as controls. After 2 weeks post-implantation, the 
functional properties of the heart were evaluated by echocardiography (Fig. 5 and Supplementary Table 
3). Left ventricles of control animals had a mean fractional shortening of 42.7 ± 1.6 and 41.6 ± 3.8 at the 
first (week 1) and the second echocardiography evaluations (week 3 after MI procedure), and an ejection 
fraction of 50.0 ± 5.0 and 34.4 ± 9.1, respectively (Fig. 5). Animals treated with CD34+ cells encapsulated 
in a fibrin gel precursor solution had a mean fractional shortening of 36.7 ± 3.4 and 44.5 ± 3.0 at first and 
second echocardiography evaluation, and an ejection fraction of 41.5 ± 6.6 and 42.7 ± 10.0, respectively 
(Fig. 5). Finally, animals treated with LPA-treated CD34+ cells and encapsulated in a fibrin gel precursor 
solution had a mean fraction shortening of 37.5 ± 1.2 and 47.0 ± 2.0 at first and second echocardiogra-
phy evaluation, and an ejection fraction of 37.3 ± 4.6 and 48.0 ± 4.3, respectively (Fig.  5). Because the 
initial fractional shortenings and ejection fractions are different between experimental groups, we used 
the individually normalized fractional shortenings and ejection fractions between the two measurement 
echocardiography events to compare the therapeutic effectiveness of the treatments. The differences 
between the means in the fractional shortenings were + 9.5 and − 1.1 in LPA-treated cells in gels and 
control (PBS) groups, respectively, being the differences statistically significant (P < 0.05). No statistical 
differences were observed between hearts treated with CD34+ cells and control (P > 0.05). Similar trend 
between groups was observed for ejection fraction. This parameter is in fact a more reliable parameter 
to evaluate left ventricle properties after myocardial infarction and after treatment since it evaluates the 
overall ventricle function rather than a section of the ventricle as in the fractional shortening. Taken 
together, the delivery of LPA-treated CD34+ cells into the infarcted heart improved cardiac fractional 
shortening and ejection fraction as compared to control (PBS) experimental group.
Figure 5. Cardiac performance after transplantation of LPA-treated CD34+ cells. Myocardial infarctions 
were induced by permanent ligation of the left anterior descending coronary artery (LAD).  
(A) Representative echocardiographic images of left ventricles before (Normal), after myocardial infarction 
without and with Gel + cells + LPA treatment. (B.1,C.1) Cardiac fractional shortening (B.1) or ejection 
fraction (C.1) in animals with (PBS, Gel + cells, Gel + cells + LPA) or without ligation of left anterior 
descending coronary artery (Normal). In LPA-treated CD34+ cells, the cells were treated with 100 μ M of 
LPA, 1 h before transplantation. Cells (1 × 106 cells) were delivered in a fibrin gel precursor solution (200 μ L) 
into the infarcted heart of nude rats. (B.2,C.2) Cardiac fractional shortening (B.2) and ejection fraction 
(C.2) at week 3 was normalized by week 1. In graphs (B,C) results are presented as mean ± SEM (n = 6–10). 
*Denotes statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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To better understand the functional improvement as assessed by echocardiography, we analyzed the 
rat hearts at 3 weeks to evaluate collagen deposition, neovascularization, CD34+ cell survival, mac-
rophage polarization (M2/M1), recruitment of primitive cardiac cells (Sca-1+ cells) and cell proliferation 
(Ki-67+ cells). Hematoxylin and eosin staining shows deposition of collagen in the infarct area for hearts 
treated with LPA-treated CD34+ cells or CD34+ cells (Fig. 6A.1,A.2). In all experimental groups, it was 
observed a chronic inflammation characterized by the presence of plasmocytes-plasma cells, fibroblasts 
as well as giant cells. Regarding neovascularization, hearts treated with gel encapsulating LPA-treated 
cells showed higher density of rat neovessels (RECA-1+ vessels) than the remaining experimental con-
ditions (Fig. 6B.1,B.2). De novo capillary-like structures were found, mainly at the borders of the infarct 
but also to a lesser extent within the infarcted area. The presence of human CD34+ cells in the infarcted 
Figure 6. In vivo survival and therapeutic mechanism of LPA-treated CD34+ cells. (A) Representative 
transverse heart sections stained with Hematoxylin and Eosin in animals treated with PBS, fibrin gel 
containing CD34+ cells or LPA-treated CD34+ cells. Samples were collected at week 3 after myocardial 
infarction. Magnification 40× (A.1) and 400× (A.2). Images in (A.2) are magnifications of regions defined 
in A.1. (B) Localization (B.1) and number (B.2) of neovessels staining for rat endothelial marker RECA-1 in 
the infarcted area (n = 3–5). (C) Localization (C.1) and number (C.2) of human CD34+ cells in the heart. In 
(B,C) scale bar corresponds to 50 μ m. *Denotes statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001.
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area was also assessed by immunohistochemistry. Human cells were only observed in hearts injected 
with LPA-treated CD34+ cells but not in hearts injected with untreated CD34+ cells (Fig.  6C.1,C.2). 
Hearts treated with gel encapsulating LPA-treated cells showed very low number of primitive cardiac cells 
(Sca-1+ cells) as well as negligible cell proliferation (Ki-67+ cells) (Fig.  7A). However, animals treated 
with fibrin gel containing LPA-treated CD34+ cells showed higher number of inflammatory cells than 
non-treated animals and lower number than animals treated with fibrin gel containing CD34+ cells 
(Fig. 7A,B). Although in all cases CD206+ macrophage cells were in higher number than CD80+ mac-
rophage cells, the number of CD206+ cells in animals with fibrin gel containing LPA-treated CD34+ cells 
was lower than the one obtained for animals treated with fibrin gel containing CD34+ cells.
Discussion
Studies have shown that CD34+ cells isolated from human cord blood augment the neovascularization 
and myocardial function in animal models of myocardial infarction6,10,11. These cells may be a suita-
ble source of cell therapy for patients that underwent a myocardial infarction and had low number of 
CD34+ cells (such as aged patients46) or impaired CD34+ function (such as patients with diabetes)47. In 
this study, we show that LPA-treated CD34+ cells have improved survival in ischemia conditions both 
in vitro and in vivo. We elucidate the mechanism underlying the survival process. Finally, we show that 
LPA-treated CD34+ cells delivered in fibrin gels, improve cardiac fractional shortening and ejection 
fraction compared to non-treated hearts (treated with PBS).
Several studies indicate that LPA pro-survival effect is mediated by G-protein-coupled receptors 
(GPCRs; i.e., LPA1, LPA2, LPA3, LPA4 and LPA5)14–16. These LPA receptors are coupled to heterotri-
meric G-proteins such as Gαi, Gαq and Gα12/13. In case of mesenchymal stem cells14 and Schwann cells16, 
LPA1 mediates the pro-survival effect. The LPA pro-survival effect is mediated by the activation of ERK 
pathway in fibroblasts15 and both Akt and ERK pathways in intestinal epithelial cells41, mesenchymal 
stem cells14,43, Schawnn cells48 and hepatocytes49. Our results show that the pro-survival effect of LPA 
in CD34+ cells is mainly mediated by PPAR-γ . Previous studies50, as well as the results obtained in the 
current work, show that CD34+ cells express PPAR-γ . PPAR-γ is a nuclear receptor that binds to specific 
DNA regulatory elements forming heterodimers with the retinoid X receptor50. Since LPA is a phos-
pholipid, it can cross the cell membrane and activates intracellular receptors29,30. LPA-induced PPAR-γ 
activation has been reported before to mediate the effect of LPA in cell migration36 but, to the best of our 
knowledge, was never evaluated in the context of cell survival. Mesenchymal stem cells do not express 
PPAR-γ 50, which might explain their insensitivity to this signaling pathway.
The activation of PPAR-γ in CD34+ cells activates both pro-survival pathways ERK and Akt and 
inhibits cell apoptosis decreasing Bax and caspase 9 expression. These results are in line with the acti-
vation of both pro-survival pathways in cardiomyocytes after the activation of PPAR-γ signaling51 and 
the anti-apoptotic role of LPA on intestinal epithelial cells and T cells by preventing translocation of the 
apoptosis regulator Bax from cytosol to mitochondria41.
Figure 7. In vivo therapeutic mechanism of LPA-treated CD34+ cells. After myocardial infarction, 
left ventricles were treated with PBS, fibrin gel containing CD34+ cells or LPA-treated CD34+ cells. 
(A) Representative images of heart rats treated with fibrin gel containing LPA-treated CD34+ cells and 
immunostained for CD206, CD80, Ki-67 and Sca-1. (B) Quantification of staining for CD206 and CD80 in 
hearts from 3–5 different animals and more than 3 sections for each animal. Score 0, 1, 2 and 3 means that 
0%, below 10%, between 10 and 50% and above 50% of the cells stained for the corresponding marker. The 
quantification was performed by a pathologist. *Denotes statistical significance: *P < 0.05, **P < 0.01.
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The mechanisms underlying the proliferative effect by LPA are diverse and depend on cell type 
and culture conditions. Activation of GPCR-dependent (LPA2 and LPA3 receptors52 and downstream 
Gα1253) or GPCR-independent54 signaling pathways have been documented to mediate the proliferation 
of LPA-treated cells. Downstream signaling pathways include the activation of ERK, protein kinase C, 
Akt, β -catenin, Ca2+ mobilization and Rho A pathways52,53,55. In the present work, LPA induces CD34+ 
cell proliferation under hypoxia and serum-deprived conditions. Cell cycle analyses after 24 h of hypoxia 
show that LPA-treated cells enter S phase and consequently G2M phase faster than non-treated cells. 
Further experiments are needed to evaluate whether cell proliferation is mediated by PPAR-γ signal-
ing. It is important to note that PPAR-γ agonists such as adiponectin and thiazolidinediones have been 
described to increase the number of CD34+ cells56.
LPA is unable to maintain the undifferentiated state of CD34+ cells. Our results show that with or 
without LPA treatment, CD34+ cells spontaneously differentiate into mast cells and cells of myeloid 
lineage (essentially neutrophils and monocytes). Previously, it was shown that LPA (5 μ M) increased the 
differentiation of human mononuclear cells into mast cells when the cells were cultured in the presence 
of stem cell factor (SCF), IL-6 and IL-10 for 2 weeks57. The capacity of LPA to enhance erythropoiesis in 
cord-blood-derived human hematopoietic stem cells has also been demonstrated21. This effect was medi-
ated by the activation of LPA3 receptor. The differentiation protocol consisted in 3 steps, and involved 
different culture media supplemented with SCF, erythropoietin, IL-3, vascular endothelial growth factor 
and insulin-like growth factor II. Finally, during the preparation of this work, it was shown that LPA 
(1 μ M) enhanced myeloid but not lymphoid differentiation of CD34+ cells20. These studies have been 
carried out in normoxia for 4 weeks, involved the use of feeder layers (OP9 stromal cell line) and cul-
ture media supplemented with growth factor combinations permissive for both myeloid and lymphoid 
differentiation (thrombopoietin, Flt3 ligand and IL-7). In the present work, we have performed our 
studies in hypoxia (initial 24 h) followed or not by 5 days of culture in normoxia, the cells were cul-
tured in the absence of feeder layers, and culture media (X-Vivo medium) without any growth factor/
cytokine supplements. Therefore, the differences observed between the results in our work and the previ-
ous ones are due to differences in cell culture conditions. It should be noted that our goal was to evaluate 
CD34+-lineage commitment after culture in hypoxia and serum-deprived conditions and not the effect 
of LPA in CD34+ differentiation protocols having different differentiating agents.
LPA modulates differently cytokine release in CD34+ cells and CD34+ cells encapsulated in fibrin gels. 
It is recognized by several studies that the regenerative effect of transplanted CD34+ cells in myocardium 
after infarction is mediated by its paracrine effect4,58,59. Recruitment of monocytes/macrophages was sig-
nificantly enhanced in human CD34+-transplanted murine hearts after infarction and this effect seems 
to be mediated by human cytokines MCP-1 and IL-845. In addition, blocking vascular endothelial growth 
factor secreted by human CD34+ cells abolished the functional (ejection fraction) improvement exerted 
by the stem cells in the murine infarcted heart59. Exosomes secreted by CD34+ cells may also represent 
a significant component of the paracrine effect of stem cells and mediate angiogenesis processes58. Our 
results indicate that LPA-treated CD34+ cells secreted higher levels of IL-6, IL-8 and G-CSF during the 
first 12 h than non-treated cells. However, at time 24 h, LPA-treated CD34+ cells secreted lower levels of 
all the measurable cytokines such as G-CSF, IFN-γ , IL-6, IL-8, IL-17, MCP-1, MIP-1β , and TNF-α than 
non-treated cells. Importantly, we demonstrated that the secretion profile of LPA-treated CD34+ cells was 
mediated by PPAR-γ signaling pathway. Previous studies have shown that LPA induced the expression of 
MCP-1 and IL-8 in human umbilical vein endothelial cells (HUVECs) through a Gi,o-, Rho- and nuclear 
factor (NF)κ B-dependent mechanisms60. In a separate study, LPA (from 1 to 25 μ M) enhanced IL-8 and 
MCP-1 expression in both EAhy926 (endothelial cell line) and HUVECs through Gi,o-, LPA1-, LPA3- and 
PPAR-γ -dependent pathways36. In both studies, the secretion of MCP-1 and IL-8 peaked before 12 h of 
cell treatment with LPA. Further, LPA induced the secretion of IL-6 and IL-8 by mature dendritic cells61. 
In the current work, the demonstration that LPA-treated CD34+ cells secrete higher levels of IL-6 and 
IL-8 during the first 12 h might be beneficial for the recruitment of monocytes/macrophages, key cellular 
players in the regeneration process45.
Because LPA-treated CD34+ cells were injected in a myocardial infarction animal model in a fibrin 
gel, we evaluated their secretome. Our results highlight significant differences in the secretome of 
LPA-treated CD34+ cells in suspension or encapsulated in fibrin gels. First, encapsulation of the cells 
in fibrin gels changed the magnitude and profile of cytokines secreted by non-treated and LPA-treated 
CD34+ cells. It is unclear the impact of these changes in the regenerative potential of CD34+ cells in the 
heart. It is likely that the differences in the secretome of CD34+ cells in suspension and encapsulated in 
fibrin gels are due to cell-matrix interactions, but further studies should be done in the near future to 
clarify this issue. Second, IL-13 was only observed in cells (either treated or not with LPA) encapsulated 
in fibrin gels. IL-13 is a protector of vascular injury having a regulatory role in the biosynthesis of fibrin-
ogen62. IL-13 also stimulates the migratory properties of hematopoietic progenitor cells63. It is interesting 
to note that a very recent study has shown that IL-13 is important for cardiac regeneration64. Therefore, 
we speculate that the secretion of IL-13 induced in CD34+ cells encapsulated in fibrin gel might be 
important for the regeneration of the heart. Third, although the secretory ability of the encapsulated cells 
is reduced in vitro, in conditions that there is no degradation of the extracellular matrix, it is expected 
that in vivo conditions, in the context of a rich metalloprotease environment, the secretory ability will 
be different. Further in vivo testing needs to be performed to clarify this issue.
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LPA-treated CD34+ cells entrapped in fibrin gels survived for 3 weeks. Although some studies showed 
that CD34+ cells can persist in the heart for up to 12 months following injection into the peri-infarct 
zone of several combined immunodeficient mice59, other studies have shown that most of CD34+ cells 
die after few days of transplantation in the infarcted heart due to ischemia6. Because paracrine effects 
mediate the regenerative properties of CD34+ cells, it is important to maintain their survival in the 
heart. Here, we show that LPA-treated CD34+ cells have enhanced survival in the infarcted heart rela-
tively to non-treated CD34+ cells. Previous studies have used several strategies to increase cell survival 
such as cell conditioning (ex: heat shock, hypoxic pre-conditioning, hypoxia inducible factor-1, eryth-
ropoietin), anti-apoptotic pathways (Rho-associated kinase inhibition, TGF-β 2 treatment, p38 MAPK 
inhibition), pro-survival cocktails (Akt and Bcl overexpression, cyclosporine, ZVAD-fmk, insulin-like 
growth factor-1), co-transplant of cells (mesenchymal cells, fibroblasts, endothelial progenitor cells), 
improving cell retention (ex: injectable hydrogels), among others65. Unfortunately, very few studies have 
used pro-survival strategies for CD34+ cells. These included the use of hydrogels to protect CD34+ cells 
from anoxia-induced apoptosis66, co-culture with endothelial cells9, treatment with prostaglandin E2 67, 
and activation of NF-κ B/Rel transcription factors by amifostine68. In the current work, we have used 
a cost effective biomolecule present in the human body that shows higher pro-survival activity than 
known CD34+ cell pro-survival molecules including prostaglandin E2 67. The pro-survival activity of LPA 
has been recently demonstrated in mesenchymal stem cells transplanted in myocardium after infarct40.
Hearts treated with fibrin gel containing LPA-treated CD34+ cells as well as in the other experimental 
conditions (non-treated hearts or hearts treated with CD34+ cells) showed low levels of cardiac primitive 
cells (Sca-1+ cells) as well as cell proliferation at week 3. However, hearts treated with fibrin gel contain-
ing LPA-treated CD34+ cells or non-treated CD34+ cells show higher number of macrophage cells, and 
in particular M2 macrophages (CD206+ cells), than non-treated hearts. Previous studies have shown that 
optimum outcome after myocardial infarction depends on a coordinated healing response that balances 
debris removal by macrophages. M1 macrophages promote inflammation and ECM destruction while 
M2 macrophages facilitate ECM reconstruction, cell proliferation, and angiogenesis69. Therefore, our 
results indicate that the healing response is superior in hearts treated with CD34+ cells than non-treated 
hearts.
Conclusions
In this work, we show that LPA enhances the survival and modulates the secretion of pro-inflammatory 
cytokines in CD34+ cells cultured in ischemic conditions, i.e., in hypoxia and serum-deprivation cultured 
conditions. In contrast to other cell types, including mesenchymal stem cells, CD34+ cell survival and 
cytokine secretion are mainly mediated by the activation of PPAR-γ and not GPCR signaling pathways. 
The activation of PPAR-γ seems to induce both the activation of Akt and ERK signaling pathways and 
the inhibition of mitochondrial apoptotic pathway (i.e. decreasing the expression of BAX and CASP9). 
Under hypoxia and serum-deprivation culture conditions, LPA induces CD34+ cell proliferation, but 
is unable to maintain their undifferentiated state. In addition, during the first 12 h of LPA treatment, 
CD34+ cells secrete higher levels of IL-6, IL-8 and G-CSF pro-inflammatory cytokines than non-treated 
cells; however, at time 24 h, LPA-treated CD34+ cells secrete lower levels of all the measurable cytokines 
such as G-CSF, IFN-γ , IL-6, IL-8, IL-17, MCP-1, MIP-1β and TNF-α than non-treated cells. Our in vivo 
results show that LPA-treated CD34+ cells have superior survival than non-treated cells, hence being able 
to contribute to the preservation of cardiac function after infarction.
Materials and Methods
Isolation of CD34+ cells from UCB. All human umbilical cord blood samples were collected from 
donors, who signed an informed consent form, in compliance with Portuguese legislation. The collection 
methods were authorized and carried out in accordance with the approved guidelines and regulations by 
the ethical committee of Maternity Daniel de Matos (Coimbra) and Hospital Infante D. Pedro (Aveiro). 
The samples were stored in sterile bags containing 35 mL of citrate-phosphate-dextrose anticoagulant 
solution. CD34+ cells were isolated from mononuclear cells, obtained from UCB samples after Ficoll/
Histopaque-1077 Hybri Max (Sigma-Aldrich, Missouri, USA) density gradient separation. CD34+ cells 
were positively selected (2 times) using the mini-MACS immunomagnetic separation system (Miltenyi 
Biotec, Bergisch Gladbach, Germany), according to the manufacturer’s recommendations. CD34+ cells 
were immediately used for cell encapsulation studies or in vivo experiments without further treatment. 
The cells isolated were above 95% of purity for CD34 antigen as confirmed by FACS.
Cell survival analyses with different drugs. UCB CD34+ cells were suspended in X-Vivo medium 
(Lonza, Basel, Switzerland; 1 × 106 cells/mL, i.e., 2 × 105 cells per well of a 96-well plate containing 200 μ L 
of X-Vivo medium) supplemented or not with one of the following drugs: Navitoclax (ABT-263), 10 μ M 
in 0.01% DMSO X-Vivo, Selleckchem, Germany; Nebivolol, 10 μ M in 0.01% DMSO X-Vivo, Selleckchem; 
INO1001, 10 μ M in 0.01% DMSO X-Vivo, Selleckchem; Irbesartan, 10 μ M in 0.01% DMSO X-Vivo, 
Selleckchem; VX-702, 10 μ M in 0.01% DMSO X-Vivo, Selleckchem; recombinant human erythropoietin, 
0.25 UI/mL in X-vivo, Sigma-Aldrich, Missouri, USA; 16,16-Dimethyl Prostaglandin E2, 10 μ M in 0.01% 
DMSO X-Vivo, Calbiochem, California, USA and LPA, 10 μ M in X-vivo, Sigma-Aldrich. The cells were 
incubated for 1 h in normoxia conditions (21% O2, 5% CO2, 37 °C) followed by their incubation in a 
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hypoxia chamber for 24 h (0.5% of O2 and 5% of CO2), in the presence or absence of pharmacological 
drugs. Cell survival was determined by annexin V/propidium iodide (PI) (Invitrogen, California, USA) 
staining, using the FACS Calibur cytometer and CellQuest software (BD Biosciences, New Jersey, USA). 
Annexin V is a phospholipid-binding protein with specificity for phospatidyl serine, one of the earliest 
makers of cellular transition to an apoptotic state. This phospholipid is translocated from the inner to 
the outer leaflet of the plasma membrane70. PI passes through the membranes of necrotic cells and 
intercalates into nucleic acids due to decreased integrity of the plasma and nuclear membranes71. CD34+ 
cells (200.000 cells) were suspended in annexin binding buffer (200 μ L) supplemented with Annexin V 
(3.5 μ L). The tubes were incubated for 10 min in the dark and then 2 μ L of a propidium iodide stock solu-
tion (1 mg/mL) was added before the samples were analyzed by flow cytometry. Approximately 20.000 
events were collected in each analysis.
Cell survival analyses in hypoxia and normoxia conditions. UCB CD34+ cells were suspended in 
X-Vivo medium, i.e., 2 × 105 cells per well of a 96-well plate containing 200 μ L of X-Vivo medium with or 
without LPA 100 μ M (in 0.01% DMSO X-Vivo). The cells were incubated in normoxia (21% O2, 5% CO2, 
37 °C) conditions for 1 h. Then, the plates were incubated in hypoxic (0.5% O2, 5% CO2, 37 °C) or nor-
moxic (21% O2, 5% CO2, 37 °C) conditions for 24 h. LPA was maintained in the culture medium during 
the 24 h period. Cell survival was determined by annexin V/propidium iodide (PI) as described before.
Cell survival analyses: effect of hypoxia/normoxia time. UCB CD34+ cells were suspended in 
X-Vivo medium, i.e., 2 × 105 cells per well of a 96-well plate containing 200 μ L of X-Vivo medium with 
or without LPA 100 μ M (in 0.01% DMSO X-Vivo). The cells were incubated in normoxia (21% O2, 5% 
CO2, 37 °C) conditions for 1 h. Then, the plates were incubated in hypoxia (0.5% O2, 5% CO2, 37 °C) for 
1 or 3 days, or in hypoxia for 1 day followed by 3 days in normoxia. LPA was maintained in the culture 
medium during the 24 h period. Cell survival was determined by annexin V/propidium iodide (PI) as 
described before.
Cell survival analyses: effect of LPA concentration. UCB CD34+ cells were suspended in X-Vivo 
medium, i.e., 2 × 105 cells per well of a 96-well plate containing 200 μ L of X-Vivo medium supplemented 
with LPA 1, 5, 10 and 100 μ M (in 0.01% DMSO X-Vivo). The cells were incubated in normoxia (21% O2, 
5% CO2, 37 °C) conditions for 1 h. Then, the plates were incubated in hypoxic (0.5% O2, 5% CO2, 37 °C) 
conditions for 24 h. LPA was maintained in the culture medium during the 24 h period. Cell survival was 
determined by annexin V/propidium iodide (PI) as described before.
Cell survival: mechanism. UCB CD34+ cells were suspended in X-Vivo medium, i.e., 2 × 105 cells 
per well of a 96-well plate containing 200 μ L of X-Vivo medium supplemented with one of the following 
antagonists: MK2206 (3 μ M, Selleckchem), PD98059 (60 μ M, CaymanChem, Michigan, USA), GW9662 
(50 μ M, Calbiochem), Y-2762/ROCK (50 μ M, Calbiochem), Ki16425 (10 μ M, Selleckchem) or 1-Bromo-
3(S)-hydroxy-4-(palmitoyloxy)butyl]phosphonate (BrP-LPA) (1.5 μ M, Echelon Biosciences Inc.). After 
10 min of incubation, LPA 100 μ M (in 0.01% DMSO X-Vivo) was added and the cells incubated in nor-
moxia (21% O2, 5% CO2, 37 °C) conditions for 1 h. Then, the plates were incubated in hypoxic (0.5% O2, 
5% CO2, 37 °C) conditions for 24 h. Antagonists and LPA were maintained in the culture medium during 
the 24 h period. Cell survival was determined by annexin V/propidium iodide (PI) as described before.
Cell survival: gene analyses (VEGFA, LPARs, BAX, CASP9, CCNG2). UCB CD34+ cells were 
suspended in X-Vivo medium, i.e., 2 × 105 cells per well of a 96-well plate containing 200 μ L of X-Vivo 
medium with or without LPA 100 μ M (in 0.01% DMSO X-Vivo). The cells were incubated in normoxia 
(21% O2, 5% CO2, 37 °C) conditions for 1 h. Then, the plates were incubated in hypoxia (0.5% O2, 5% 
CO2, 37 °C) for 4, 8, 12 or 24 h. LPA was maintained in the culture medium during the 24 h period. 
Cells were collected and RNA extracted according to the protocol below. In case of cells encapsulated in 
fibrin gels, the constructs were centrifuged and incubated with lysis buffer and glass beads (Advanced 
Tecnologies) until the whole gel was depolymerized. RNA was then extracted according to the protocol 
below.
CD34+ cell proliferation analyses. UCB CD34+ cells were suspended in X-Vivo medium, i.e., 
2 × 105 cells per well of a 96-well plate containing 200 μ L of X-Vivo medium with or without LPA 100 μ M 
(in 0.01% DMSO X-Vivo). The cells were incubated in normoxia (21% O2, 5% CO2, 37 °C) conditions for 
1 h. Then, the plates were incubated in hypoxia (0.5% O2, 5% CO2, 37 °C) for 1 day followed by 6 days 
in normoxia. LPA was maintained in the culture medium during the assay. Cell count was performed 
with a hemocytometer.
Cell cycle analyses by flow cytometry. UCB CD34+ cells were suspended in X-Vivo medium, i.e., 
2 × 105 cells per well of a 96-well plate containing 200 μ L of X-Vivo medium with or without LPA 100 μ M 
(in 0.01% DMSO X-Vivo). The cells were incubated in normoxia (21% O2, 5% CO2, 37 °C) conditions 
for 1 h and then in hypoxia (0.5% O2, 5% CO2, 37 °C) for 1 day. Cells were fixed by adding cold 70% 
(w/v) ethanol, drop by drop to the tube wall while vortexing to avoid the formation of cell aggregates. 
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Cells were kept at − 20 °C until they were further processed for analysis. For staining, cells were washed 
once with PBS, incubated for 30 min at room temperature with a solution containing propidium iodide 
(PI, 20 μ g/mL, Sigma), 200 μ g/mL DNAse-free RNAse and 0.1% (v/v) Triton in PBS and analyzed with a 
FACS Calibur (BD Biosciences). CellQuest software (BD Biosciences) was used to quantify the percent-
age of the different cell cycle phases.
Cell differentiation analyses. UCB CD34+ cells were suspended in X-Vivo medium, i.e., 2 × 105 cells 
per well of a 96-well plate containing 200 μ L of X-Vivo medium with or without LPA 100 μ M (in 0.01% 
DMSO X-Vivo). The cells were incubated in normoxia (21% O2, 5% CO2, 37 °C) conditions for 1 h. Then, 
the plates were incubated in hypoxia (0.5% O2, 5% CO2, 37 °C) for 1 day or incubated in hypoxia for 
1 day followed by 6 days in normoxia. In both cases, cells were characterized by FACS using a 4-tube 
characterization protocol. The following CD34+ sub-populations were identified by a FACS Canto II flow 
cytometer (BD Biosciences): uncommitted (more immature) precursors, neutrophil precursors, B cell 
precursors, monocytic precursors, plasmacytoid dendritic cells precursors, erythroid precursors, baso-
phil precursors and mast cell precursors. The markers used are listed in Supplementary Tables 1 and 2. 
FACSDiva (BD Biosciences) and Infinicyt™ , v.1.5 (Cytognos SL, Salamanca, Spain) software’s were used 
for acquisition and analysis, respectively.
Preparation of fibrin gels. Fibrin gels were formed by crosslinking of fibrinogen (Sigma-Aldrich) in the 
presence of thrombin (Sigma-Aldrich), as reported before by us9. Briefly, the fibrinogen solution was pre-
pared by dissolving human fibrinogen in Tris-buffered saline (TBS) (Sigma-Aldrich), pH 7.4 (20 mg/mL), 
and then sterilized by filtering through 0.22 μ m syringe filter (Acrodisc, Washington, USA). Fresh throm-
bin solutions were prepared by dissolving human thrombin in TBS at pH 7.4 at a concentration of 50 U/
mL. Fibrin gels (200 μ L for in vivo and 50 μ L for in vitro) were prepared by mixing three different com-
ponents: fibrinogen (10 mg/mL), CaCl2 (Merck, New Jersey, USA) (2.5 mM) and thrombin (2 U/mL). 
This solution was allowed to polymerize at 37 °C and 95–98% relative humidity.
Cell survival: CD34+ cells encapsulated in fibrin gel. UCB CD34+ cells encapsulated in a fibrin 
gel (i.e. 2 × 105 cells per 50 μ L of gel) were suspended in X-Vivo medium (200 μ L) with or without LPA 
100 μ M (in 0.01% DMSO X-Vivo). The cells were incubated in normoxia (21% O2, 5% CO2, 37 °C) con-
ditions for 1 h and then in hypoxia (0.5% O2, 5% CO2, 37 °C) for 1 day. At the end, the survival of the 
cells was evaluated by fluorescence microscopy using AnnexinV/PI staining.
Cytokine secretion analyses. Cell culture supernatants were evaluated for the presence and concen-
trations of cytokines using a Bio-Plex Pro Human Cytokine 17-Plex Panel Assay (Bio-Rad, California, 
USA), according to manufacturer’s instructions, in a Bio-Plex 200 System (Bio-Rad). The human group I 
17-plex panel consisted of the following analytes: interleukin-1β (IL-1β ), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8; 
IL-10, IL-12(p70), IL-13, IL-17, granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage 
colony-stimulating factor (GM-CSF), interferon-γ (IFN-γ ), monocyte chemotactic protein (monocyte 
chemotactic activating factor [MCP-1 (MCAF)], macrophage inflammatory protein-β (MIP-1β ) and 
tumor necrosis factor-α (TNF-α ). Cell culture supernatants were collected, centrifuged to remove pre-
cipitates and frozen at − 80 °C. A standard range of 0.2 to 3.200 pg/mL was used. Samples and controls 
were run in triplicates, standards and blanks in duplicates.
Caspase activity. Cells in suspension and cells encapsulated in fibrin gels were prepared as before. 
After 24 h in hypoxia, the amount of apoptotic cells was determined using Caspase-Glo® 9 assay 
(Promega, WI, USA) according to manufacturer’s instructions. The assay depends on the generation of 
a “glow-type” luminescent signal produced by the luciferase reaction between luminogenic caspase-9 
substrate and caspase-9 enzyme present in the cells. Suspended cells and cells encapsulated in fibrin gels 
were cultured as described in previous sections for 24 h. Equal volumes of Caspase-Glo® reagent and 
cell culture medium were mixed in each well and incubated at room temperature for 2 min on an orbital 
shaker to induce cell lysis. Then, the cells were transferred into opaque-walled multiwell plates and lumi-
nescence measurements were done using a LUMIstar Luminometer (BMG LABTECH, Germany). The 
medium without cells was used as a blank control.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. Total 
RNA in cells was extracted by using the RNeasy Mini Kit (Qiagen, Hilden, Germany), according to 
manufacturer’s instructions. In all cases, cDNA was prepared from 1 μ g total RNA using Taqman Reverse 
transcription reagents (Applied Biosystems, California, USA). Quantitative PCR (qPCR) was performed 
using Power SYBR Green PCR Master Mix (Applied Biosystems, California, USA) and the detection was 
carried out in a 7500 Fast Real-Time PCR System (Applied Biosystems). Quantification of target genes 
was performed relatively to the reference human GAPDH gene: = −( − )relative expression 2[ Ct Ct ]sample GADPH . 
The mean minimal cycle threshold values (Ct) were calculated from four independent reactions. Primer 
sequences are published as supporting information (Supplementary Table 4).
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Myocardial infarction animal model. Experiments were performed on 20 adult male Rowett nude 
rats (Crl:NIH-Foxn1rnu) (Charles River Laboratories International) weighing between 180 and 250 gr. In 
accordance to the Directive 2010/63/EU rats were acclimatized for two weeks before animal procedures, 
housed in groups of 2 in individual ventilated cages (IVC) type III rat cages (Tecniplast SRL, Italy) on 
enriched corn cob bedding with 65 air changes per hour, ambient temperature between 21–22 °C and 
a relative humidity of 40–60% and an artificial light dark cycle of 12/12 hours. The animals had free 
access to water and standard diet ad libitum. Methods involved in this project were authorized and 
carried out in accordance with the approved guidelines and regulations by the national animal welfare 
body from Direção Geral de Alimentação e Veterinária (DGAV). Surgery instruments were sterilized by 
autoclave. Rowett nude rats (Crl:NIH-Foxn1rnu) were anaesthetized with ketamine (75 mg/kg, IP) and 
dexmedetomidine (0.375 mg/kg, IP) and placed in supine position for tracheal intubation. A 16-Gauge 
intravenous catheter with a 70 mm long wire stylet with a 30 mm hub was used as an endothreacheal 
tube. The catheter hub was connected to the respirator and rats were mechanical ventilated. Anaesthesia 
was afterwards maintained by 1–2% isoflurane in balanced oxygen. The abdomen and anterior chest 
were scrubbed with betadine and wiped with 70% alcohol (with several cycles of betadine scrub followed 
by alcohol rinse and application of betadine solution). The heart was approached either by a transverse 
abdominal incision (diaphragmatic incision) with the animal’s back gently extended over a soft towel or 
laterally via the intercostal space 4–5. A small diaphragmatic incision was made to create a pericardial 
window. A 5 mm incision was made in the pericardium with an 11–0 scalpel. Myocardial infarction was 
induced by permanent ligation of the left anterior descending coronary artery with a 6–0 Proline suture, 
2–3 mm below the origin of the artery. Pallor and regional wall motion abnormality of the left ventricle 
confirmed occlusion. The pericardium was left open or removed to avoid tamponade. The pleural space 
was evacuated with an 18-gauge sterile needle and 3-ml syringe following closure of the pleural cavity. 
Abdominal wall and subcutaneous tissue were closed with Vicryl 4–0 followed by a subcuticular closure 
with Vicryl 4–0. The animal was extubated and then allowed to recover. Each animal was maintained 
during surgical procedures and recovery under warming pads until awake and able to ambulate. Two or 
three days after recovery from this procedure, animals underwent echocardiographic evaluation under 
ketamine/midazolam anesthesia. Echocardiographic evaluation was performed by using a Vivid i ultra-
sound equipment and a 10S probe (GE healthcare). Animals meeting the echocardiographic inclusion 
criterion (fractional shortening below 50%) were stratified into one of 3 groups. One week after MI 
procedure the rats were subjected to a second thoracotomy followed by direct injection of 200 μ L of ther-
apeutic agent using Micro Fine Plus 30-gauge needle (BD Bioscience) into the myocardium. Two weeks 
after implantation, the surviving rats (3 weeks after MI) were submitted to a second echocardiographic 
evaluation under ketamine/midazolam anesthesia and fractional shortening was accessed. At week 4 after 
MI procedure (3 weeks after implantation) animals were euthanized with lethal dose of anesthetics. The 
hearts were harvested and processed for histological analysis. One group of heart was placed Optimal 
Cutting Temperature (OCT) and immediately frozen and stored at − 80 °C. Other group was stored in 
4% paraformaldehyde (with 10% formalin) and stored at room temperature.
Histology and immunohistochemistry analyses. The hearts were explanted from the rats and 
frozen at − 80 °C. For further processing they were thawed in formaldehyde (BDH Prolabo, 4%) and 
embedded in paraffin (Merck, Histosec) which was followed by Microtome sectioning (Leica). Transverse 
sections of 10 μ m were placed on silane-coated slides (Leica) for Immunostaining or uncoated slides 
for H&E and Masson’s Trichrome staining and allowed to dry overnight. After deparaffinization and 
rehydration, samples were stained with H&E solution (Sakura- Tissue- Tek® DRS™ ) or Masson´s 
Trichrome. Labelled Streptavidin and Biotin methodology was used for immunostainning, following 
sample pre-treatment for antigen unmasking. CD34+ antigen unmasking was achieved by slide treatment 
with EDTA for 20 min while RECA-1 antigen unmasking was achieved by treatment with Pronase E 
for 10 min at room temperature. Endogenous peroxidase activity was quenched using 15 min incuba-
tion in 3% diluted hydrogen peroxide (H2O2). For blocking non-specific binding, Ultra V Block (Ultra 
Vision Kit; TP-015-HL) was applied to the sections and they were incubated with primary antibodies, 
anti-Human CD34+ (Dako, 1:25, 30 min) and anti-rat RECA-1 (Abcam, 1:200, 30 min). The slides were 
counterstained with hematoxylin, dehydrated and mounted.
In case of CD206, Sca-1, CD80, and Ki-67 immunohistochemistry, the antigens were unmasked by 
enzyme treatment (10 min, Pronase E, in case of CD206), bond epitope retrieval solution 1 (pH 6, 20 min, 
in case of Sca-1) or bond epitope retrieval solution 2 (pH 8, 20 min, in case of CD80 or Ki-67). Endogenous 
peroxidase activity was quenched using 5 min incubation in 3% (v/v) diluted H2O2. Immunohistochemical 
staining was performed with Bond Polymer Refine Detection™ (DS9800; Leica Biosystems, Newcastle 
Ltd, United Kingdom) according to manufacturer’s instructions on BondMax. Sections were incubated 
with anti-rat primary antibodies, CD206 (Santa Cruz, 1:100, 30 min), CD80 (Santa Cruz, 1:75, 30 min), 
Sca-1 (Abcam, 1:300, 30 min) and Ki-67 (Santa Cruz, 1:50, 30 min). After staining, the slides were coun-
terstained with hematoxylin (5 min), dehydrated and mounted. In parallel, known positive and negative 
controls were used. The intensity of the staining was graded semi-quantitatively on a four point scale: 
0 − negative; 1+ < 10%, 2+ 10–50%, 3+ > 50% percentage of immunostained cells.
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Statistical analyses. Statistical analyses were performed using GraphPad PRISM software. One-way 
ANOVA with post Newman-Keuls testing or Dunnett multiple comparison testing was used to examine 
statistical differences between multiple groups. Unpaired t-test was used to examine statistical differences 
between two independent groups.
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